Most Read Articles
Pearl Toh, Yesterday
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
4 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 6 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.

Psoriasis, psoriatic arthritis predispose patients to liver disease

26 Nov 2017

Patients with psoriasis (PsO) or psoriatic arthritis (PsA) appear to be at greater risk of developing serious liver disease compared with those who have rheumatoid arthritis (RA), as shown in a study.

The study followed for an average of 6 years patients with PsO (n=197,130), PsA (n=12,308) or RA (n=54,251) and matched unexposed controls (n=1,279,754) for the development of any liver disease (nonalcoholic fatty liver disease [NAFLD], cirrhosis and viral hepatitis, among others)—the primary outcome.

In the cohort, RA patients were more likely to be older, female and have more medical comorbidities. On the other hand, PsO and PsA patients receiving systemic therapy (ST) had higher body mass index (BMI). ST was prescribed in 6 percent in the PsO group, 53 percent in the PsA group and 61 percent in the RA group. Methotrexate was the most frequently used drug.

Multivariable Cox proportional hazard models showed that the risk of incident liver disease was elevated in all disease groups than in controls, with the exception of RA group prescribed an ST (adjusted hazard ratio [aHR], 0.96; 95 percent CI, 0.83 to 1.12).

The highest risk of incident liver disease was observed in the PsO group with ST (aHR, 1.97; 1.63 to 2.38), followed by the PsA group with ST (aHR, 1.67; 1.29 to 2.15), RA group without ST (aHR, 1.49; 1.26 to 1.76), PsA group without ST (aHR, 1.38; 1.02 to 1.86) and PsO group without ST (aHR, 1.37; 1.29 to 1.45).

Specifically, NAFLD (37.85 percent) was the most frequently diagnosed liver disease subtype, followed by alcoholic liver disease (18.53 percent), unknown causes (10.35 percent), viral aetiologies (7.76 percent), biliary disease (4.33 percent) and autoimmune liver disease (0.60 percent).

The present data lend empirical support to the long-held expert opinion that patients with PsO may be more predisposed to liver disease than patients with RA, researchers noted.

Physicians should inform patients regarding the increased risk of liver disease and recommend weight loss and moderation of alcohol use, and consider minimizing use of nonsteroidal anti-inflammatory drugs in combination with other hepatotoxic medications, they continued.

More studies are warranted to elucidate the role of inflammation in liver disease and, conversely, the role the liver plays in perpetuating inflammation in PsO, PsA and RA, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, Yesterday
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
4 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 6 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.